Lilly's Retevmo succeeds in lung cancer patients with RET
US pharma major Eli Lilly (NYSE: LLY) on Friday announced top-line results from the LIBRETTO-431 study evaluating Retevmo (selpercatinib) versus platinum-based chemotherapy plus pemetrexed – with or without Merck & Co’s mega blockbuster PD-1 inhibitor Keytruda (pembrolizumab) – as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).
The US Food and Drug Administration (FDA) granted accelerated approval to Retevmo for adults with locally advanced or metastatic solid tumors with a RET gene fusion in September last year.
Retevmo was brought to Lilly through its $8 billion acquisition of Loxo Oncology in early 2019. The drug generated $192 million in 2022, with the analysts projecting sales will rise to roughly $700 million in 2030.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze